State MI
Clinical Trials in Michigan
Michigan is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Michigan and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 322 actively recruiting studies with Michigan sites out of 322 registered in total. The busiest research areas in Michigan are Advanced Solid Tumors, Small Cell Lung Cancer, Parkinson Disease. Leading sponsors running trials in the state include University of Michigan, National Cancer Institute (NCI), AstraZeneca. By stage, Michigan trials break down as Phase 1 (65), Phase 2 (105), Phase 3 (96), Phase 4 (10).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Michigan
Frequently Asked Questions — Clinical Trials in Michigan
How many clinical trials are currently recruiting in Michigan?
ClinicalMetric currently tracks 322 actively recruiting clinical trials with at least one location in Michigan. The total number of registered studies—including active but not currently enrolling trials—is 322. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Michigan?
Michigan hosts clinical trials across a broad range of medical conditions, including Advanced Solid Tumors, Small Cell Lung Cancer, Parkinson Disease, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Michigan serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Michigan?
To join a clinical trial in Michigan, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Michigan maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Michigan
NCT06701669 Phase 2
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Parid...
Condition
Acute Respiratory Distress Syndrome (ARDS)
Enrollment
200 pts
Location
United States
Sponsor
PPD Development, LP
NCT07361562 Phase 1
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Soli...
Condition
Advanced Solid Tumor, Adult
Enrollment
100 pts
Location
United States
Sponsor
Cogent Biosciences, Inc.
NCT07455383 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolep...
Condition
Narcolepsy Type 1
Enrollment
150 pts
Location
United States, Australia, Belgium
Sponsor
Alkermes, Inc.
NCT04879329 Phase 2
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th...
Condition
Urothelial Carcinoma
Enrollment
372 pts
Location
United States, Argentina, Australia
Sponsor
Seagen, a wholly owned subsidi
NCT06772623 Phase 1, Phase 2
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab ...
Condition
Non Small Cell Lung Carcinoma
Enrollment
252 pts
Location
United States, Argentina, Australia
Sponsor
AbbVie
NCT07769151 N/A
Recruiting
BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy
Condition
Mortality Prediction
Enrollment
124 pts
Location
United States
Sponsor
Henry Ford Health System
NCT06804824 Phase 1
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-1596...
Condition
Advanced Solid Tumors
Enrollment
220 pts
Location
United States, Australia
Sponsor
Vividion Therapeutics, Inc.
NCT07470853 Phase 1
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With A...
Condition
PROC
Enrollment
265 pts
Location
United States
Sponsor
Whitehawk Therapeutics, Inc.
NCT06719713 N/A
Recruiting
Store Safely: Rural Firearm Injury Prevention for Families
Condition
Firearm Injury
Enrollment
600 pts
Location
United States
Sponsor
University of Michigan
NCT05763251 N/A
Recruiting
Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults
Condition
Invasive Candidiasis
Enrollment
420 pts
Location
United States, Australia
Sponsor
Arkansas Children's Hospital R
NCT07804615 Phase 2
Recruiting
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adu...
Condition
PARKINSON DISEASE (Disorder)
Enrollment
80 pts
Location
United States, Canada
Sponsor
Vima Therapeutics
NCT06874335 Phase 1
Recruiting
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Condition
Solid Tumor
Enrollment
140 pts
Location
United States
Sponsor
Biohaven Therapeutics Ltd.
NCT06790693 Phase 3
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor a...
Condition
Breast Cancer
Enrollment
450 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT06750185 Phase 1, Phase 2
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for A...
Condition
Advanced Solid Tumor
Enrollment
248 pts
Location
United States, Australia
Sponsor
BioNTech SE
NCT07295847 Phase 1, Phase 2
Recruiting
A Study of AZD0120 in Autoimmune Diseases
Condition
Systemic Sclerosis
Enrollment
27 pts
Location
United States, Australia, Germany
Sponsor
AstraZeneca
NCT05561387 Phase 3
Recruiting
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)...
Condition
Plasma Cell Myeloma
Enrollment
510 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT06626919 Phase 1
Recruiting
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell...
Condition
Muscular Diseases
Enrollment
30 pts
Location
United States
Sponsor
Kite, A Gilead Company
NCT05455619 Phase 1, Phase 2
Recruiting
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A...
Condition
HR+/HER2-negative Breast Cancer
Enrollment
52 pts
Location
United States
Sponsor
SynDevRx, Inc.
NCT07518186 Phase 3
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or ...
Condition
Multiple Myeloma
Enrollment
700 pts
Location
United States, Australia, Brazil
Sponsor
Janssen Research & Development
NCT07296744 N/A
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous...
Condition
Coronary Artery Disease
Enrollment
358 pts
Location
United States
Sponsor
Supira Medical
NCT06952699 Phase 2
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Condition
Narcolepsy Type 2
Enrollment
88 pts
Location
United States, China, France
Sponsor
Takeda
NCT07062471 N/A
Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL)...
Condition
Carotid Artery Calcification
Enrollment
185 pts
Location
United States
Sponsor
Shockwave Medical, Inc.
NCT05898399 Phase 1, Phase 2
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Condition
Advanced Solid Tumor
Enrollment
181 pts
Location
United States, Spain, United Kingdom
Sponsor
Artios Pharma Ltd
NCT06291155 Phase 4
Recruiting
Mechanism of SGLT2 Inhibition in the Kidney
Condition
Type 2 Diabetes
Enrollment
20 pts
Location
United States
Sponsor
University of Michigan
NCT06479135 Phase 3
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With ...
Condition
Myelofibrosis
Enrollment
600 pts
Location
United States, Australia, Austria
Sponsor
Kartos Therapeutics, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology